SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

The World Cup warning: Riots don’t start in the streets. They start online

“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

“There is no better solution for Zim than the one we created”

Buzz

Most popular

Daily

Weekly

1

"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"

2

Iron Dome and Iron Beam maker Rafael unveils new weapon against the drone threat

3

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

4

Echo: “Employees have become very good at identifying performative culture”

5

More than 50 years after its debut, Israel's Kfir fighter jet gets a new lease on life

Nucleai

6 stories about Nucleai

Spatial AI biomarker startup Nucleai raises $14 million led by Merck’s VC arm

Leveraging AI and machine learning, Nucleai analyzes pathology images and spatial data at the cellular and tissue levels. The proprietary technology extracts detailed patterns and features from medical images, offering insights into the tumor microenvironment, cellular morphology, and spatial relationships between different cell types

How have international stakeholders responded to Startup Nation since 7/10?

26.10.23|James Spiro

Nucleai helped its global customers and investors understand the magnitude of October 7 by comparing it to 9/11 in the U.S.

Nucleai raises $33 million for spatial biology drug development platform

22.03.22|Meir Orbach

The technology developed at the Israeli startup allows better prediction of the patient's response to specific oncological treatment, saves on the ongoing process of testing different drugs and improves the chances of the development of new cancer drugs

צוות Nucleai מימין לוטן חורב אלירון אמיר אבי ויידמן אלברט אכטרברג

The Israeli startup using spatial biology to provide better cancer treatment

02.01.22|Yafit Ovadia

Nucleai is looking at the way cells interplay and are interspersed within human tissue to develop precision medicine solutions

צוות Nucleai מימין לוטן חורב אלירון אמיר אבי ויידמן אלברט אכטרברג

AI cancer treatment startup Nucleai raises $6.5 million in series A round

07.07.20|Meir Orbach

Nucleai’s software uses computer vision and machine learning algorithms to predict the progress of cancerous tumors as well as the patient’s immune system response in order to determine the most efficient treatment

CTech’s Monday Israeli Tech News Roundup

Israel wants to lure U.S. scientists with $100 thousand grants. Barclays ends partnership with Ness Technologies